Mankind Pharma partners with Denovo Sciences on AI drug discovery

Economic Times reported that Mankind Pharma partnered with Denovo Sciences to start an AI-driven drug discovery program. The companies say Denovo's platform will generate and evaluate molecular candidates while Mankind's R&D and clinical teams guide, validate, and refine the work through a human-in-the-loop process. The program is aimed at shortening early discovery timelines, improving lead quality, and filtering out weak candidates earlier in development.

Key details: Mankind Pharma and Denovo Sciences announced the partnership on July 1, The program uses AI to generate and evaluate molecular candidates, Mankind says the goal is faster discovery cycles and stronger candidate selection.

Why it matters: The deal shows AI drug-discovery adoption broadening beyond global pharma into Indian R&D programs that still keep scientific review in the loop.